Differential susceptibility of human cancer cell lines to wild-type tanapoxvirus infection.
Tanapoxvirus (TPV) is a member of the genus Yatapoxvirus in the family Poxviridae and is endemic to equatorial Africa. This disease is restricted to human and non-human primates, producing a mild febrile illness characterized by a single or more rarely additional pock-like lesions on the extremities. While there are several studies elucidating the replication cycle and host range of TPV, there is currently no standardized investigation comparing the ability of TPV to successfully replicate in a variety of tumor cell lines. This study examined the cytopathic effect and calculated the efficiency of TPV replication in vitro using 14 different human cancer cell lines. TPV replicates efficiently in some human tumor cells, and is restricted in others when measured by viral titer at 7 days post infection. Results described here clearly demonstrate that TPV replication in one glioblastoma cell line (U-373), and one colorectal cancer cell line (HCT-116) is more productive than in owl monkey kidney cells (OMK). Replication in two renal cancer cell lines (ACHN and Caki-1) is also increased when compared to OMK. TPV infection produced the greatest change in cellular morphology in U-373 cells, and to a much lesser degree in the breast cancer cell lines T-47D and MCF-7, and in the ovarian cancer line SK-OV3. Negligible change was noted in glioblastoma line U-87, breast cancer line MDA-MB-435, osteosarcoma line HOS, melanoma line SK-MEL5, colorectal cancer line COLO205, and prostate cancer line PC3. The cell lines least permissive to TPV replication were the glioblastoma (U-87) and melanoma (SK-MEL5) cell lines.
Lee
Hui Lin
HL
Laboratory of Virology, Department of Biological Sciences, Western Michigan University, Kalamazoo, MI 49008, USA.
Essani
Karim
K
Ann Surg Oncol. 2008 Aug;15(8):2329-35
18454298
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14950-5
9843996
Virology. 2007 Nov 10;368(1):32-40
17632198
Can J Microbiol. 1999 Jan;45(1):92-6
10349725
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5
11572954
Br Med J. 1971 Feb 13;1(5745):363-8
5541925
Virology. 1989 Sep;172(1):116-24
2773312
J Infect Dis. 1969 Jan;119(1):80-8
4303797
J Neurovirol. 2007 Dec;13(6):549-60
18097886
J Virol. 1998 Oct;72(10):8374-9
9733888
Clin Cancer Res. 2008 Feb 15;14(4):1218-27
18281557
Nat Med. 2005 Nov;11(11):1188-96
16227992
J Virol. 2007 Feb;81(3):1251-60
17108021
Bacteriol Rev. 1966 Mar;30(1):33-66
5324648
Virus Res. 2007 Oct;129(1):11-25
17574698
Cancer Res. 2007 Sep 15;67(18):8818-27
17875723
J Hyg (Lond). 1972 Mar;70(1):23-32
4335340
Virology. 2001 Mar 15;281(2):170-92
11277691
Cancer Res. 2005 Nov 1;65(21):9982-9990
16267023
Biochim Biophys Acta. 2008 Jan;1784(1):228-37
17905673
J Virol. 2003 Dec;77(24):13335-47
14645589
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5
16537421
J Virol. 1999 Oct;73(10):8750-61
10482629
Virology. 1999 Nov 25;264(2):298-318
10562494
BMC Bioinformatics. 2003 Sep 17;4:42
13678422
J Am Vet Med Assoc. 1967 Oct 1;151(7):833-8
4293246
Bull World Health Organ. 1985;63(6):1027-35
3011301
Oncogene. 2005 Oct 6;24(44):6719-28
16007163
J Virol. 2001 Nov;75(21):10300-8
11581398